Beauticians being trained to spot early signs of skin cancer
Beauty professionals are being trained to help spot the early signs of skin cancer.
A new scheme launched on the Isle of Wight by the Lighthouse Clinic and Lighthouse Education aims to equip beauticians with the skills to identify potentially cancerous moles and lesions, helping to refer clients for early medical assessment and potentially lifesaving treatment.
The scheme uses the MASCED (Melanoma and Skin Cancer Early Detection) Accredited Training, developed by the national skin cancer charity Skcin, and is specifically designed for the beauty industry.
A spokesman for the Lighthouse Clinic said: "We are excited to partner with Skcin to bring this training to the Isle of Wight.
"The beauty industry is perfectly placed to play a vital role in spotting the early signs of skin cancer.
"Together, we're training eyes to save lives."
The campaign highlights the unique position of beauty therapists, nail technicians, hairdressers, and barbers, who regularly observe their clients' skin and may notice changes that clients themselves have missed.
Lighthouse Education has funded 100 free places for Isle of Wight professionals to take part in the training, which takes about 60 minutes to complete online.
Participants receive a certificate of accreditation and a practical guide covering sun safety, UV exposure risks, and identifying types of skin cancer.
The first salon to complete the training was Becalmed Medispa in Cowes.
Marie Tudor, chief executive officer of Skcin, said: "We are delighted Lighthouse Education has funded the training for salons and clinics on the Isle of Wight.
"This is an incredible opportunity to help promote the early detection of skin cancer and sun safety with the people living on the island."
She emphasised the vital role beauty professionals can play in skin surveillance and early intervention.
Marie said: "Anyone working in this sector, undertaking close contact skin services, has a key role to play in undertaking skin surveillance, highlighting any concerns with their clients, and signposting appropriately."
The MASCED training has already proven effective elsewhere in the UK.
In one case, a beautician identified concerns in eight clients, three of whom were later diagnosed with melanoma and received timely treatment as a result.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Alan Jackson's final tour is over. Why his health condition has him calling it a career
Country music icon Alan Jackson, a Georgia native from Newnan, has officially played his last show on his "Last Call: One More for the Road Tour." After a 40-year journey in music, Jackson, 66, announced that the show on May 17 would be his last on tour—ever. The tour began in 2022 and continued through May 2025. The decision to tour one last time came despite his ongoing battle with a chronic neuropathy condition, which he first revealed in 2021. In addition to the final show of his tour, Jackson made a special announcement during the May 17 concert: he will return to Nashville in the summer of 2026 for one final performance. The exact date and location for the show will be revealed at a later time. For over a decade, Jackson has battled Charcot-Marie-Tooth disease, an illness that has affected his ability to move and stay balanced on stage. In a 2021 interview with the "TODAY" show's Jenna Bush Hager, Jackson said he inherited the disease from his father, and it has affected several members of his family. He was diagnosed with the disease in 2011. According to the National Institute of Neurological Disorders and Stroke, Charcot-Marie-Tooth disease causes a range of sensory and motor symptoms, including numbness, tingling, pain, muscle weakness and atrophy — deterioration in cells, tissues, and organs. The disease can also cause foot deformities that worsen over time. In some cases, the disease can affect the nerves that control automatic body functions, leading to problems with sweating and dizziness. Muscle weakness from the disease typically begins in the feet and lower legs during the teen years or early adulthood, though symptoms can appear at any age, reported the institute. Over time, the weakness may spread to the fingers, hands, and arms. Some individuals with CMT might be unaware they have the condition, while others may experience physical disabilities. Symptoms may include: Weakness or paralysis in the foot and lower leg muscles A high-stepping walking pattern with frequent tripping or falling Balance problems Foot deformities, like high arches and curled toes Lower legs with an "inverted champagne bottle" shape due to the loss of muscle bulk Trouble feeling heat, cold and touch Possible hand weakness and atrophy Decreased ability to sense vibrations or know body position Scoliosis Hip displacement A chronic shortening of muscles or tendons around joints Muscle cramps Nerve pain Charcot-Marie-Tooth is mostly an inherited disorder, meaning people with a family history of the disease are more likely to develop it. If a person has the disease, that doesn't mean their children will have it, but it does increase the risk, said the institute. There is no cure for the disease, however treatment programs like physical and occupational therapy can help manage symptoms and help people maintain quality of life, said the institute. Orthopedic devices and surgery may help with symptoms, and doctors may prescribe medication for severe nerve pain. Vanessa Countryman is the Trending Topics Reporter for the the Deep South Connect Team Georgia. Email her at Vcountryman@ This article originally appeared on Savannah Morning News: Alan Jackson health condition: Why he's calling it a career from touring
Yahoo
4 days ago
- Yahoo
Beauticians being trained to spot early signs of skin cancer
Beauty professionals are being trained to help spot the early signs of skin cancer. A new scheme launched on the Isle of Wight by the Lighthouse Clinic and Lighthouse Education aims to equip beauticians with the skills to identify potentially cancerous moles and lesions, helping to refer clients for early medical assessment and potentially lifesaving treatment. The scheme uses the MASCED (Melanoma and Skin Cancer Early Detection) Accredited Training, developed by the national skin cancer charity Skcin, and is specifically designed for the beauty industry. A spokesman for the Lighthouse Clinic said: "We are excited to partner with Skcin to bring this training to the Isle of Wight. "The beauty industry is perfectly placed to play a vital role in spotting the early signs of skin cancer. "Together, we're training eyes to save lives." The campaign highlights the unique position of beauty therapists, nail technicians, hairdressers, and barbers, who regularly observe their clients' skin and may notice changes that clients themselves have missed. Lighthouse Education has funded 100 free places for Isle of Wight professionals to take part in the training, which takes about 60 minutes to complete online. Participants receive a certificate of accreditation and a practical guide covering sun safety, UV exposure risks, and identifying types of skin cancer. The first salon to complete the training was Becalmed Medispa in Cowes. Marie Tudor, chief executive officer of Skcin, said: "We are delighted Lighthouse Education has funded the training for salons and clinics on the Isle of Wight. "This is an incredible opportunity to help promote the early detection of skin cancer and sun safety with the people living on the island." She emphasised the vital role beauty professionals can play in skin surveillance and early intervention. Marie said: "Anyone working in this sector, undertaking close contact skin services, has a key role to play in undertaking skin surveillance, highlighting any concerns with their clients, and signposting appropriately." The MASCED training has already proven effective elsewhere in the UK. In one case, a beautician identified concerns in eight clients, three of whom were later diagnosed with melanoma and received timely treatment as a result.
Yahoo
21-05-2025
- Yahoo
Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary
New recruit expands senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT-100216, into the clinic for the treatment of Charcot-Marie-Tooth Disease and continues building its pipeline in neurodegenerative and cardio-metabolic diseases Subsidiary Augustine Therapeutics Denmark ApS, located in Copenhagen, Denmark to serve as hub for the company's research work in cardio-metabolic medicine LEUVEN, Belgium – 21 May 2025 – Augustine Therapeutics NV ('Augustine' or 'the Company'), a biotechnology company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, today announced the appointment of Rie Schultz Hansen, PhD, as Chief Scientific Officer, effective immediately. With more than 20 years' experience in drug discovery and early-stage drug development, Rie is an experienced executive with a strong background in cardio-metabolic and inflammation-driven diseases as well as peptide therapeutics. Prior to joining Augustine, she served as the Chief Scientific Officer at Aelin Therapeutics, where she played a key role in developing a degrader platform based on induced protein aggregation to neutralize disease-causing proteins. Later, she spearheaded an entrepreneurial initiative advancing AI/ML-based solutions derived from Aelin Therapeutics technology, securing initial funding and forging a collaboration for assay development and high-throughput screening capabilities. Rie spent the majority of her career at the peptide development specialist Zealand Pharma (CPH: ZEAL) where she worked across multiple functional areas, mainly focused on cardiovascular, metabolic and inflammatory diseases. Roles at Zealand Pharma included Innovation Officer, Vice President, Head of Discovery and Innovation, and Interim Chief Scientific Officer, governing the preclinical portfolio until CTA/IND submission and developing and implementing the strategy for research and chemistry for pre-clinical projects. Throughout her career Rie has maintained a strong connection with academia and has served for several years as a member of the Danish Cardiovascular Academy Grant committee. In addition, Augustine today announced the founding of a Copenhagen, Denmark based subsidiary, Augustine Therapeutics Denmark ApS, which will serve as the company's hub for research related to cardio-metabolic diseases. Gerhard Koenig, PhD, CEO of Augustine Therapeutics commented: 'Following the latest appointments of Virginie Cartage as Chief Financial Officer and Dr. Andy Hu as Chief Business Officer, I am pleased to further bolster our executive team. Rie's expertise will be instrumental in advancing Augustine's lead candidate, AGT-100216, through a Phase I/II proof-of-concept clinical trial in CMT and the Company's two other programs in discovery targeting peripherally-restricted and blood-brain barrier-penetrant HDAC6i for undisclosed neurodegenerative and cardio-metabolic indications. Rie's deep knowledge around the biology of cardio-metabolic diseases will provide critical leadership as we as we grow into our next stage as a clinical stage company with a deep HDAC6i pipeline pursuing a range of clinical applications.' Rie Schultz Hansen, PhD, Chief Scientific Officer of Augustine Therapeutics added: 'Augustine is at a significant juncture in its development. With the Company's novel and next generation approach to selectively inhibit HDAC6 and successful Series A fundraise, I am eager to leverage my experience in early-stage drug development and maximise the potential of the Company's highly differentiated pipeline as we proceed into the clinic. Furthermore, the establishment of our Danish subsidiary will drive the for the expansion of our efforts in applying HDAC6i in cardio-metabolic diseases and allow us to tap into the unique depth of cardio-metabolic R&D capabilities in the Danish region.' Rie received her Master's in Biology and PhD at the Faculty of Medicine, University of Copenhagen. She is also a board member of the Peptide Therapeutics Foundation and a member of the DCAcademy Grant Committee (University of Copenhagen) and obtained her post doctorate in cardiovascular research. Media Contacts: Augustine TherapeuticsGerhard Koenig, CEOE-mail: info@ ICR Healthcare Amber Fennell E-mail: augustinetx@ About Augustine TherapeuticsAugustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, neurodegenerative and cardio-metabolic diseases through its next-generation approach to selectively inhibit HDAC6. Augustine's HDAC6 inhibitors have been purposefully designed to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. Augustine's lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth (CMT) disease. With its novel non-hydroxamate, non-hydrazide producing chemotype, Augustine's HDAC6 approach is selective, avoids the limitations of other chemotypes, and built for chronic diseases. With this novel approach, the Company will also be targeting diseases beyond CMT, including neurodegenerative and cardio-metabolic diseases. Augustine Therapeutics was founded on the ground-breaking research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium. The Company raised an oversubscribed EUR 78 million / USD 85 million Series A financing round in March 2025, led by Novo Holdings and Jeito Capital and supported by existing investors Asabys Partners, Eli Lilly and Company, AdBio partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, the US-based Charcot-Marie-Tooth (CMT) Research Foundation and Newton Biocapital. For more information visit in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
